Literature DB >> 33915186

Considerations for the selection of co-formers in the preparation of co-amorphous formulations.

Dani Lakshman Yarlagadda1, Vullendula Sai Krishna Anand1, Athira R Nair1, K S Navya Sree1, Swapnil J Dengale1, Krishnamurthy Bhat2.   

Abstract

Co-amorphous drug delivery systems are evolving as a credible alternative to amorphous solid dispersions technology. In Co-amorphous systems (CAMs), a drug is stabilized in amorphous form using small molecular weight compounds called as co-formers. A wide variety of small molecular weight co-formers have been leveraged in the preparation of CAMs. The stability and supersaturation potential of prepared co-amorphous phases largely depend on the type of co-former employed in the CAMs. However, the rationality behind the co-former selection in co-amorphous systems is poorly understood and scarcely compiled in the literature. There are various facets to the rational selection of co-former for CAMs. In this context, the present review compiles various factors affecting the co-former selection. The factors have been broadly classified under Thermodynamic, Kinetic and Pharmacokinetic-Pharmacologically relevant parameters. In particular, the importance of Glass transition, Miscibility, Liquid-Liquid phase separation (LLPS), Crystallization inhibition has been deliberated in detail.
Copyright © 2021 Elsevier B.V. All rights reserved.

Keywords:  Co-amorphous system; Co-former; Glass forming ability; LLPS/GLPS; Miscibility; Supersaturation

Year:  2021        PMID: 33915186     DOI: 10.1016/j.ijpharm.2021.120649

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

Review 1.  Co-amorphous Drug Delivery Systems: a Review of Physical Stability, In Vitro and In Vivo Performance.

Authors:  Qin Shi; Yanan Wang; Sakib M Moinuddin; Xiaodong Feng; Fakhrul Ahsan
Journal:  AAPS PharmSciTech       Date:  2022-09-19       Impact factor: 4.026

2.  Prediction and Preparation of Coamorphous Phases of a Bislactam.

Authors:  Luke I Chambers; Osama M Musa; Jonathan W Steed
Journal:  Mol Pharm       Date:  2022-06-22       Impact factor: 5.364

3.  Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends.

Authors:  Nuno F da Costa; Rolf Daniels; Ana I Fernandes; João F Pinto
Journal:  Pharmaceutics       Date:  2022-07-23       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.